Skip to main content
Premium Trial:

Request an Annual Quote

Silicon Valley Biosystems' Dx Lab Receives CLIA Certification

NEW YORK (GenomeWeb News) – Silicon Valley Biosystems today said that its in silico diagnostics laboratory has received CLIA certification from the California Department of Public Health.

The firm performs next-generation sequencing-based diagnostics on patient samples at the lab. It runs SV Bio's GermlineDx NGS interpretation platform, providing a "turnkey solution for clinical grade analysis and interpretation of single-gene, multi-gene, whole-exome, or whole-genome assays for germline indications, such as Mendelian disease diagnosis, carrier testing, hereditary cancer risk assessment, and pharmacogenomic applications," the firm said in a statement.

SV Bio also has a CLIA-certified ultra-high-throughput NGS wet lab for customers who need a complete solution, including generation of the genetic sequence, the company said.

Foster City, Calif.-based SV Bio was launched earlier this year and provides genomic data at the point of care. It and Mayo Clinic have an agreement to use each other's technologies to improve accessibility and the clinical use of next-generation sequencing for patients.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.